NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/17/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization356 mln
Float12.84 mln
Earnings Date08/17/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
90
/ 100
Top performer
Debt / Equity
-1.04
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
Business Description
Galectin Therapeutics is a clinical-stage drug development company focused on finding new treatments for fibrosis, cancer, and related conditions. Its primary drug candidate, belapectin, is currently being tested in multiple clinical trials targeting liver disease, severe skin conditions, and certain cancers. The company also operates a joint venture with SBH Sciences through Galectin Sciences LLC to develop oral treatments that block galectin-3, a protein involved in disease progression. Founded in 2000 and headquartered in Norcross, Georgia, the company was previously called Pro-Pharmaceuticals before adopting its current name in 2011.
